Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
This study shows that gut bacteria accumulate host-targeted drugs intracellularly, which affects the therapeutic effect of the drug as well as metabolite secretion of the accumulating bacteria without much having an impact on bacterial growth.
This month’s Genome Watch highlights how recent advances in computational identification of biosynthetic gene clusters (BGCs), and in their experimental manipulation, are opening new avenues to access novel secondary metabolites.
Elucidating the structure and function of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins is vital for understanding the molecular mechanisms of viral replication and COVID-19 pathogenesis, and could lead to the development of novel therapeutics. In this Review, Yang and Rao delineate the structural features of SARS-CoV-2 from the whole viral particle to the individual viral proteins and discuss their functions as well as their potential as targets for therapeutic interventions.
Biofuels produced by conversion of biomass by engineered microorganisms have the potential to replace fossil fuels and reduce carbon emissions. In this Review, Keasling and colleagues discuss engineering of metabolic pathways to produce advanced biofuels and approaches to reduce metabolite toxicity and cost and increase titre, rate and yield.
In this Review, Galán discusses the mechanisms by which Salmonella enterica subsp. enterica serovar Typhimurium triggers inflammation in the intestinal tract through the activities of effector proteins as well as the mechanisms that are aimed at recovering host homeostasis after the inflammatory response.
Small antibacterial molecules termed bacteriocins can influence microbiome composition by providing an advantage to bacteriocin producers over bacteriocin-sensitive strains. In this Review, Peschel and colleagues provide an overview of the types of bacteriocins, their costs and benefits, and how they may provide new avenues for antibacterial drug development.